JP2015521183A - ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 - Google Patents

ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 Download PDF

Info

Publication number
JP2015521183A
JP2015521183A JP2015512071A JP2015512071A JP2015521183A JP 2015521183 A JP2015521183 A JP 2015521183A JP 2015512071 A JP2015512071 A JP 2015512071A JP 2015512071 A JP2015512071 A JP 2015512071A JP 2015521183 A JP2015521183 A JP 2015521183A
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
series consisting
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015512071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521183A5 (https=
Inventor
マルク・ナツァレ
デトレフ・コツィアン
アンドレアス・エバース
ヴェルンガルト・チェヒティズツキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2015521183A publication Critical patent/JP2015521183A/ja
Publication of JP2015521183A5 publication Critical patent/JP2015521183A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2015512071A 2012-05-18 2013-05-16 ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 Ceased JP2015521183A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305551.9 2012-05-18
EP12305551 2012-05-18
PCT/EP2013/060169 WO2013171316A1 (en) 2012-05-18 2013-05-16 Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation

Publications (2)

Publication Number Publication Date
JP2015521183A true JP2015521183A (ja) 2015-07-27
JP2015521183A5 JP2015521183A5 (https=) 2016-06-23

Family

ID=48446367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512071A Ceased JP2015521183A (ja) 2012-05-18 2013-05-16 ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用

Country Status (4)

Country Link
US (1) US9346757B2 (https=)
EP (1) EP2850062B1 (https=)
JP (1) JP2015521183A (https=)
WO (1) WO2013171316A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7118642B2 (ja) 2014-08-08 2022-08-16 アリ リサーチ ソシエタ ア レスポンサビリタ リミタータ センプリフィカタ 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9346762B2 (en) 2012-05-18 2016-05-24 Sanofi Pyrazole derivatives and their use as LPAR5 antagonists
PL4038052T3 (pl) * 2019-10-02 2024-08-26 Domain Therapeutics Antagoniści receptora ep4 prostaglandyny e2 (pge2)
GB201914585D0 (en) * 2019-10-09 2019-11-20 Heptares Therapeutics Ltd Prostaglandin ep4 receptor antagonist compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060819A1 (en) * 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
JP2011507916A (ja) * 2007-12-26 2011-03-10 サノフィ−アベンティス Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US7279478B2 (en) 2002-09-04 2007-10-09 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
EP2118066A1 (en) 2007-02-09 2009-11-18 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JP5509100B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用
EA019711B1 (ru) 2008-03-07 2014-05-30 Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А. ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОБУСЛОВЛЕННЫХ ЭКСПРЕССИЕЙ МСР-1, СХ3CR1 ИЛИ р40
GEP20135879B (en) 2009-08-03 2013-07-10 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Method of 1-benzyl-3-hydroxymethyl-1h-indazole preparation, derivatives thereof, and required magnesium intermediates
ES2530345T3 (es) 2010-09-02 2015-03-02 Merck Patent Gmbh Derivados de pirazolopiridinona como antagonistas del receptor del LPA
US9346762B2 (en) 2012-05-18 2016-05-24 Sanofi Pyrazole derivatives and their use as LPAR5 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060819A1 (en) * 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
JP2011507916A (ja) * 2007-12-26 2011-03-10 サノフィ−アベンティス Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ILIC, MILOS ET AL.: "Thrombin inhibitors with lipid peroxidation and lipoxygenase inhibitory activities", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21(16), JPN6017006564, 2011, pages 4705 - 4709, ISSN: 0003653579 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7118642B2 (ja) 2014-08-08 2022-08-16 アリ リサーチ ソシエタ ア レスポンサビリタ リミタータ センプリフィカタ 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物

Also Published As

Publication number Publication date
EP2850062A1 (en) 2015-03-25
WO2013171316A1 (en) 2013-11-21
US9346757B2 (en) 2016-05-24
US20150141471A1 (en) 2015-05-21
EP2850062B1 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
CN116082303B (zh) 新型氧代吡啶类化合物及其中间体和应用
KR101589332B1 (ko) ２ｈ-크로멘 화합물 및 그의 유도체
JP6257596B2 (ja) ピラゾール誘導体およびｌｐａｒ５アンタゴニストとしてのその使用
JP5309033B2 (ja) ヘテロアリールシクロプロパンカルボキサミド及び薬剤としてのその使用
CZ299600B6 (cs) Heterocyklické slouceniny obsahující dusík jako inhibitory p38 proteinkinázy a farmaceutické prostredky s jejich obsahem
JP2011511046A (ja) ５，６−ビスアリール−２−ピリジン−カルボキシアミド誘導体、この調製、およびウロテンシンｉｉ受容体の拮抗剤としてのこの治療的用途
JP2012149085A (ja) Ｐ３８のインヒビターとしてのピリジン誘導体
JP2004536057A (ja) ｐ３８インヒビターとして使用する２，５−二置換ピリジン、ピリミジン、ピリダジンおよび１，２，４−トリアジンの誘導体
CN116262736B (zh) 新型氧代吡啶类化合物及其制备方法和用途
JP2015521183A (ja) ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
KR102947730B1 (ko) 염증성 기도 질환의 치료를 위한 오토탁신 (atx) 조절제로서의 1-(6-(메톡시)피리다진-3-일)사이클로프로판-1-카르복사미드 유도체
EP0861831A1 (en) Heteroaryl-substituted acryloylguanidine derivatives and medicinal composition thereof
KR102825587B1 (ko) 혈소판 응집 억제 활성을 가지는 신규 메타-쿠마릴아마이드 유도체, 이를 유효성분으로 함유하는 약학적 조성물 및 이의 제조방법
JP6238970B2 (ja) ベンゾ［１，３］ジオキシン誘導体およびｌｐａｒ５アンタゴニストとしてのその使用
JP2005500284A (ja) Ｐ３８のイソキノリンインヒビター
CN117164566B (zh) 一种氧代哒嗪类化合物及其制备方法和用途
KR101664281B1 (ko) 3,4-다이클로로페닐기를 포함하는 아세트아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
JPWO1996023773A1 (ja) ４−オキソ−２−ブテン酸誘導体
JPWO1999015520A1 (ja) 縮合または非縮合ベンゼン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171003

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20180227